Electrical Impedance Spectroscopy (EIS) cancer diagnostic device technology

Zilico Ltd has developed an innovative cancer diagnostic device technology that employs Electrical Impedance Spectroscopy (‘EIS’) within a device that seeks to improve and extend current cancer screening programmes, by providing accurate and objective results in real-time. The initial focus of the Company is to address the detection of cervical cancer and oral cancer, and the Company plans to apply the same approach to oesophageal, anal, vaginal and vulva cancers.  The Company’s device, called ZedScan, examines the electrical resistance properties of human tissues, through the measurement and interpretation of electrical resistance of that tissue and then provides an objective method to differentiate between normal, pre-cancerous, and cancerous cells.

  • Product

    Technology Growth EIS
  • Sector

    Diagnostic Technology
  • Status

  • HMRC

    Advanced Assurance